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Abstract 
Despite high coverage of pertussis vaccine, B. pertussis has remained endemic and adults are recognized as reservoir for 
infection among incompletely immunized infants. Between November 15th 2004 and November 14th 2006, 37 general 
practitioners, attending 56,658 adults, recruited all patients with persistent cough. A diagnosis of pertussis was considered in 
those with an unexplained cough, lasting 14 or more days and a positive polymerase chain reaction (PCR) or enzyme-linked 
immunosorbent assay (ELISA) IgG anti-Pertussis Toxin (PT). During the period of the study 86 patients presented with 
persistent cough (106 cases per 100,000 person-years). According to laboratory criteria, 35% were classified as associated to B. 
pertussis, with an incidence of 34 cases per 100,000 person-years (95% CI 23 to 46 per 100,000 person-years). 
© 2009 Elsevier B.V. 
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1. Background 
The introduction of mass vaccination of children in the mid-20th century decreased the incidence of pertussis[1], 
but despite high vaccination coverage B. pertussis has remained endemic and epidemic outbreaks[2], deaths in 
young children[3] and a shift to older age groups[4-10] are increasingly reported. Pertussis endemicity is due to the 
limited duration of protective immunity after natural infection or immunization[7, 11-14] with the consequent 
accumulation of susceptible individuals that maintain the risk of transmission in the community[15, 16]. It has been 
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suggested that B. pertussis infection is a frequent cause of persistent cough in adults[7, 17-25] and adults are 
recognized as reservoir and source of infection for incompletely immunized infants [16, 26, 27]. 
B. pertussis infection is rarely considered in the diagnosis of persistent cough in adults, and even good 
surveillance systems underestimate the number of pertussis cases in this age group[28, 29]. In order to describe the 
incidence of B. pertussis associated disease we conducted an active search of pertussis infection in adults who 
consulted their general practitioner for otherwise unexplained persistent cough.  
2. Methods 
2.1. Study population 
Between November 15th 2004 and November 14th 2006, 37 primary general practitioners, located in 23 health 
care centers, in the Autonomous Community of Valencia, Spain, attending 56,658 adults, over 17 years of age, 
prospectively recruited all those patients that attended their clinics, had been coughing for 14 days or more and 
cough could not be explained for an existing co morbidity, drug adverse effect or any other ready apparent cause. 
On the same visit, after written informed consent, data on vaccination, similar episodes, duration of cough episode, 
symptoms, antibiotic treatment and existence of household or workplace coughing contacts was obtained and serum 
and nasopharyngeal samples were collected. Investigators were contacted by phone every two weeks to ascertain 
case recruitment. The protocol of the study was approved by the Primary Health Care Research Ethics Committee. 
2.2. Laboratory methods 
IgG antibodies to B. pertussis toxin (IgG anti-PT) were determined by ELISA (Petrusscan, Euro-Diagnostica, 
Malmo, Sweden). Susceptibility to B. pertussis infection was defined as an IgG anti-PT measurement less than 0.33 
arbitrary units (AU)/ml[30]. Cut off value for a positive ELISA result was defined by the corresponding 99th IgG 
anti-PT AU/ml percentile in patients with no known recent history of pertussis or any cough disease[25, 31]. In 
order to determine IgG anti-PT levels in patients without recent episodes of persistent cough, during the second 
study year, a serum sample was obtained, after written informed consent, from 55 patients with no known recent 
history of pertussis or any cough disease and a cut off value of 0.917 AU/ml was as a positive ELISA IgG anti-PT 
result and considered indicative of current or recent infection. Bordetella pertussis PCR was determined using an in-
house procedure. We considered a diagnosis of pertussis in those patients with an otherwise unexplained cough, 
lasting 14 or more days and with at least a positive PCR or ELISA IgG anti-PT test. 
2.3. Sample size and statistical analysis 
In order to detect an incidence of at least 50 cases per 100,000 person-years, with an error of ± 20 per 100,000, 
with a two-tail 5% alpha error and 80% statistical power, a population of 50,000 persons over 17 years of age was to 
be observed. A log transformation of serological data was carried out and geometric mean concentrations were 
obtained for comparisons.  T-test was used to compare quantitative variables and simple chi-squared test to compare 
qualitative variables. To assess variables (sex, age, symptomatology and exposure) which were independently 
associated with being a pertussis case, a multivariate logistic regression was adjusted. All statistical analyses were 
carried out with STATA v.9. 
3. Results 
During the period of the study 86 patients presented to their general practitioner with persistent cough (106 cases 
of persistent cough for 100,000 person-years), 69 (80.2%) gave their consent and were included in the study, 57 
(82.6%) cases during the first and 12 (17.4%) during the second study year (Table 1). 
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3.1. Persistent cough associated with B. pertussis infection. 
Attending to laboratory criteria, 24 (34.8 %; 95% CI, 23.3% to 46.3%) patients were classified as patients with 
persistent cough associated to B. pertussis, with an incidence of 34 cases per 100,000 person-years (95% CI 23 to 46 
per 100,000 person-years). PCR was positive in one patient, IgG anti-PT in 22, and PCR and IgG anti-PT in one. 
Patients with persistent cough were more frequent during the first compared to the second study year. During the 
first year, 22 out of 57 (38.6%) patients with persistent cough were positive for IgG anti-PT or PCR compared to 2 
of 12 (16.7%) during the second study year (Table 1).The incidence of persistent cough associated with pertussis 
was seven times higher in the first compared to the second study year (41 vs. 6 per 100,000 person years; P=0.0013; 
incidence rate ratio of 6.8; 95% CI, 1.7-60.0). 
Table 1.  
Cumulative incidence rates of persistent cough cases and cases of persistent cough positive for IgG anti-PT or PCR in the first and second study 
year periods 
   Patients with persistent cough 
Period Patients included Person-years All IgG anti PT or PCR positive 
  N 
Rate per 100,000 
person years 
N (95% CI) 
N 
Rate per 100,000 
person years 
N (95% CI) 
Nov 15th  2004- 
Nov 14th 2005 56,658 53,791 57 106 (80-137) 22 41 (26-62) 
Nov 15th  2005- 
Nov 14th 2006 49,985 33,432 12 36 (19-63) 2 6 (0.7-22) 
3.2. Patient characteristics and clinical symptoms associated with B. pertussis infection. 
Sex, age, antecedents, immunization history and symptoms distributions were similar between those with and 
without laboratory criteria for pertussis. The presence of any household member with cough was clearly associated 
with a pertussis associated episode, while living alone was negatively associated (P=0.048) with pertussis. Not 
reaching significance, pertussis cases were younger (P=0.0995), whilst previous whooping cough episodes were 
more frequent (P=0.0641) in those without laboratory evidence of pertussis infection (Table2).  
3.3. Susceptibility to B. pertussis 
The percentage of pertussis susceptible patients was significantly lower in the 69 patients with persistent cough 
compared to the 55 patients with no known recent history of pertussis or any cough disease from whom the cut-off 
for a positive ELISA result was derived, 21.7% vs. 52.7% (95% CI for the difference, 14.6% to 47.4%; P=0.0003), 
being susceptible, respectively. This susceptibility pattern remained after excluding laboratory confirmed pertussis 
cases, with a difference of 31.1% vs. 52.7% (95% CI of the difference, 2.7% to 40.5%; P=0.0298). 
Considering the 69 patients with persistent cough, susceptibility was significantly related to age and study year. 
Susceptible patients with persistent cough were older than non susceptible patients (58 vs. 45 years of age; 
P=0.0199). a different pattern was observed related to the presenting period, only nine of 57 (16%) consulting their 
physicians for persistent cough during the first study year were susceptible compared to six of 12 (50%) recruited 
during the second study year (95% CI of the difference, 4.4% to 64.0%; P=0.009) 
3.4. IgG anti-PT concentrations in persistent cough patients. 
IgG anti-PT geometric mean concentration was significantly higher in patients with persistent cough compared to 
the group of 55 patients with no known recent history of pertussis or any cough disease (0.63 AU/ml vs. 0.37 
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AU/ml; P=0.0002). The prevalence of IgG anti-PT levels showed an inverse albeit not significant relationship with 
age, with higher concentrations in younger patients with persistent cough (P value for trend=0.0882). This pattern 
was reversed in the 55 patients with no known recent history of pertussis or any cough disease, were the prevalence 
of IgG anti-PT levels increased with age with a significant variability (P=0.0240) between age groups (Figure 1a and 
Figure 1b). 
Table 2.  
Characteristics of patients with persistent cough *
 Patients with persistent cough  
IgG-anti PT  
Negative Positive P-value 
N (%)  N (%)  
Age, mean (sd) 50.6 (17.9) 43.5 (17.0) 0.0995 
Previous whooping cough episodes 4 (10.3) 1 (4.2) 0.0641 
Immunised 4 (10.8) 4 (16.7) 0.202 
Lives alone 6 (15.4) 0 0.048 
Household members with cough 5 (13.2) 9 (37.5) 0.026 
Cough duration    
Mean (sd) 47.4 (24.9) 44.6 (19.4)  
Range 18-118 14-78 0.8651 
Cough paroxysms 36 (92.3) 19 (79.2) 0.128 
Whooping 8 (20.5) 3 (17.5) 0.416 
Apnea episodes 4 (10.3) 4 (16.7) 0.458 
Vomiting 10 (25.6) 8 (33.3) 0.512 
Sleep disturbance 25 (64.1) 42 (70.8) 0.582 
IgG anti pertussis toxin (AU/ml)†    
GMC (IC95%) 0.4 (0.3-0.4) 1.3 (1.0-1.7) 0.0001 
Range of values 0.14-0.92 0.17-2.99‡  
* Clinical study records missing in six patients out of 69 patients with persistent cough that gave their consent to participate in the study. 
† Serology results available for 68 out of 69 patients. 
‡ One patient had a positive PCR while ELISA IgG anti-PT was 0.17 AU/ml. After excluding this value, IgG anti-PT value range was 0.93 to 
2.99 AU/ml. 
4. Discussion 
Ours is the first study conducted in Spain to estimate the incidence of pertussis associated clinical illness in adults 
presenting to their general practitioners with otherwise unexplained persistent cough. Serological evidence of a 
recent B. pertussis infection was ascertained in a substantial proportion of otherwise unexplained persistent cough 
cases in adults. Adding to that, a similar age related serology prevalence pattern, compatible with recurring pertussis 
infection episodes has been described previously by others in other population settings[31-33]. 
4.1. Study limitations 
The estimation of pertussis in adults by epidemiologic methods is subject to limitations due incomplete case 
ascertainment, observation of small unrepresentative samples, lack of well controlled validated serologic methods, 
variability in the definition of the source population and study of different epidemic periods. This is clearly 
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exemplified by the wide range of available estimates of the incidence of pertussis in adults, with rates that go from 
50 cases per 100,000 person-years to 800 per 100,000 person-years[7, 17, 18, 21, 23].  
Our study was powered to detect even a low occurrence of cases as we followed prospectively a large and well 
defined adult population during two successive but different epidemic years. Consecutive presenting patients that 
met the case definition and accepted to participate were included and to minimize under reporting general 
practitioners participating in the study were contacted periodically. The variability in the presentation of the cases to 
their physicians during the two study periods was fully coincident with the pattern of B. pertussis cases detected by 
Spain epidemiologic surveillance systems[34, 35], albeit, the incidence of cases detected by the surveillance systems 
(0.17 per 100,000 in those older than 13 years of age) was just a small fraction of the incidence of 34 per 100,000 
person-years in 18 years old or older detected in our study. Last, a recent analysis of a well defined and controlled 
population[36] reported a percentage of clinical illness associated with pertussis (20% to 46%) consistent with our 
estimates (23% to 43%). Notwithstanding, our study was not powered enough to detect significant associations in 
clinical or disease risk factors between pertussis and non pertussis cough patients. 
4.2. Laboratory case ascertainment 
Use of a single IgG anti-PT determination for the diagnosis of pertussis in adults has been recommended by 
various authors[31, 37-39] as PCR assays are likely to become negative after a few weeks of illness or in patients 
with previous disease episodes[31] as was the case in our study, were only in two instances PCR was positive. Our 
results strongly support the recommendation to use IgG anti-PT for the serologic diagnosis of pertussis, adding to 
that we were able to detect a significant differential susceptibility profile between persistent cough patients, related 
to study period, emphasizing the sensibility of this test to detect the intensity of exposure to B. pertussis. The 
different susceptibility patterns indicate that a positive result was appropriate outside a period of high pertussis 
circulation but conservative when used in an epidemic period, giving support to the opportunity of its use to suspect 
B. pertussis in adults with persistent cough. 
4.3. Conclusion 
Adults suffer and are susceptible to pertussis infection during all their life. Serious consideration is to be given to 
IgG anti-PT ELISA determination to detect pertussis associated cough in adults. Our findings give support to the use 
of the adult formulation of the acelular pertussis vaccine in adults. 
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